Answers are grounded in this paper and cite their sources.
Review reveals variable clinical impacts and technical promise of intelligent drug monitoring systems in healthcare institutions, highlighting persistent implementation and evidentiary gaps.
: Intelligent supervision of narcotic and psychotropic drugs in medical institutions aims to balance appropriate therapeutic access with the prevention of misuse and diversion. Traditional regulatory approaches relying on manual documentation and periodic audits may be limited by delayed information exchange, fragmented data sources, and insufficient real-time monitoring. This review synthesizes current evidence on digital and intelligent supervision technologies, implementation barriers, regulatory frameworks, and evidence maturity. Electronic Prescribing for Controlled Substances and prescription drug monitoring programs have been associated with changes in prescribing patterns, although effects vary across settings and regulatory contexts. Artificial intelligence applications, including predictive analytics, natural language processing, and computer vision, have shown promising performance in selected retrospective and technical validation studies, but prospective clinical evidence remains limited. Blockchain and Internet of Things technologies are being explored for pharmaceutical traceability, auditable records, sensor-enabled monitoring, and programmable compliance workflows, although controlled-substance-specific evidence remains preliminary. Important implementation challenges include infrastructure requirements, economic costs, workforce training, legacy-system integration, data quality, cybersecurity, privacy, and algorithmic bias. Future research should prioritize standardized evaluation metrics, prospective and comparative studies, longitudinal outcome assessment, and economic evaluation. Intelligent supervision should ultimately support medication safety and regulatory oversight while preserving patient autonomy, equitable access, and professional clinical judgment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: